Advertisement

Topics

Mylan/Biocon’s Insulin Glargine Has Narrow Window For Approval In US

13:15 EDT 10 Jul 2019 | SCRIP

Thirty-month stay resulting from Sanofi’s patent lawsuit expires on 18 March 2020, two days before Mylan’s application must receive final...

      

Related Stories

 

Original Article: Mylan/Biocon’s Insulin Glargine Has Narrow Window For Approval In US

NEXT ARTICLE

More From BioPortfolio on "Mylan/Biocon’s Insulin Glargine Has Narrow Window For Approval In US"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...